265 related articles for article (PubMed ID: 17369863)
1. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
Kamezaki K; Kikushige Y; Numata A; Miyamoto T; Takase K; Henzan H; Aoki K; Kato K; Nonami A; Kamimura T; Arima F; Takenaka K; Harada N; Fukuda T; Hayashi S; Ohno Y; Eto T; Harada M; Nagafuji K
Bone Marrow Transplant; 2007 May; 39(9):523-7. PubMed ID: 17369863
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma.
Endo T; Sato N; Mogi Y; Koizumi K; Nishio M; Fujimoto K; Sakai T; Kumano K; Obara M; Ikeda H; Koike T
Bone Marrow Transplant; 2004 Apr; 33(7):703-7. PubMed ID: 14743197
[TBL] [Abstract][Full Text] [Related]
3. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
Biswas T; Dhakal S; Chen R; Hyrien O; Bernstein S; Friedberg JW; Fisher RI; Liesveld J; Phillips G; Constine LS
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):79-85. PubMed ID: 19647953
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
5. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
Hess G; Flohr T; Huber C; Kolbe K; Derigs HG; Fischer T
Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP.
Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Kim SW; Jang S; Park CJ; Chi HS; Huh J; Suh C
Transfusion; 2007 Aug; 47(8):1447-54. PubMed ID: 17655589
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R
Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
[TBL] [Abstract][Full Text] [Related]
8. Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma.
Imamura T; Yoshihara T; Morimoto A; Ishida H; Sugimoto T; Imashuku S
Pediatr Hematol Oncol; 2006; 23(1):19-24. PubMed ID: 16326408
[TBL] [Abstract][Full Text] [Related]
9. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
10. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma.
Copelan E; Pohlman B; Rybicki L; Kalaycio M; Sobecks R; Andresen S; Dean R; Koo A; Chan J; Sweetenham J; Bolwell B
Bone Marrow Transplant; 2009 Jan; 43(2):101-5. PubMed ID: 18794865
[TBL] [Abstract][Full Text] [Related]
12. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Kanaji N; Ishibashi K; Uno H; Hino N
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
Flohr T; Hess G; Kolbe K; Gamm H; Nolte H; Stanislawski T; Huber C; Derigs HG
Bone Marrow Transplant; 2002 May; 29(9):769-75. PubMed ID: 12040475
[TBL] [Abstract][Full Text] [Related]
14. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients.
Benekli M; Hahn T; Shafi F; Qureshi A; Alam AR; Czuczman MS; Bernstein ZP; Chanan-Khan AA; Becker JL; McCarthy PL
Bone Marrow Transplant; 2003 Jul; 32(2):139-43. PubMed ID: 12838277
[TBL] [Abstract][Full Text] [Related]
15. Effective in vivo purging with rituximab and autologous peripheral blood stem cell transplantation in a woman with CD5 positive primary cutaneous diffuse large B-cell lymphoma.
Goto H; Nishio M; Endo T; Sato N; Koizumi K; Fujimoto K; Sakai T; Kumano K; Obara M; Koike T
Eur J Haematol; 2005 Jun; 74(6):526-8. PubMed ID: 15876258
[TBL] [Abstract][Full Text] [Related]
16. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
Park YH; Sohn SK; Kim JG; Lee MH; Song HS; Kim MK; Jung JS; Lee JJ; Kim HJ; Kim DH
Clin Cancer Res; 2009 Mar; 15(6):2107-15. PubMed ID: 19276283
[TBL] [Abstract][Full Text] [Related]
17. [Effective combined modality therapy for a patient with primary adrenal lymphoma].
Shirao S; Kuroda H; Kida M; Watanabe H; Matsunaga T; Niitsu Y; Konuma Y; Hirayama Y; Kohda K
Rinsho Ketsueki; 2006 Mar; 47(3):204-9. PubMed ID: 16629485
[TBL] [Abstract][Full Text] [Related]
18. Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma.
Neumann F; Harmsen S; Martin S; Kronenwett R; Kondakci M; Aivado M; Germing U; Haas R; Kobbe G
Ann Hematol; 2006 Aug; 85(8):530-4. PubMed ID: 16639571
[TBL] [Abstract][Full Text] [Related]
19. The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization.
Keane C; Gibbs S; Seymour JF; Mills AK; Grimmett K; Van Kuilenberg R; Saal R; Gill D; Prince HM; Marlton P; Mollee P
Hematol Oncol; 2006 Sep; 24(3):159-63. PubMed ID: 16775841
[TBL] [Abstract][Full Text] [Related]
20. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
Gisselbrecht C
Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]